Osteomalacia Due to $1\alpha,25$-Dihydroxycholecalciferol Deficiency

ASSOCIATION WITH A GIANT CELL TUMOR OF BONE

MARC K. DREZNER and MARK N. FEINGLOS, Department of Medicine, Division of Endocrinology, Veterans Administration Hospital and Duke University Medical Center, Durham, North Carolina 27710

ABSTRACT Oncogenic osteomalacia is a syndrome in which unexplained osteomalacia remits after resection of a coexisting mesenchymal tumor. We have investigated the mechanism by which a giant cell tumor of bone caused biopsy-proved osteomalacia in a 42-yr-old woman. The biochemical abnormalities were: hypophosphatemia; decreased renal tubular maximum for the reabsorption of phosphate per liter of glomerular filtrate; negative calcium and phosphorus balance; hyperaminoaciduria; and subnormal calcemic response to exogenously administered parathyroid hormone. Malabsorption, hypophosphatasia, fluorosis, and acidosis were excluded as causes of the osteomalacia. Serum $25$-hydroxycholecalciferol was normal ($27\pm1$ ng/ml). However, the serum concentration of $1\alpha,25$-dihydroxycholecalciferol was low ($1.6\pm0.1$ ng/100 ml). Oral administration of physiological amounts of $1\alpha,25$-dihydroxycholecalciferol resulted in resolution of the biochemical abnormalities of the syndrome and healing of the bone pathology. We suggest that tumor-induced inhibition of $1\alpha,25$-dihydroxycholecalciferol synthesis caused the osteomalacia. The causal role of the tumor was proved by demonstrating that resection was accompanied by roentgenographic evidence of bone healing and maintenance of normal serum phosphorus; renal tubular maximum for the reabsorption of phosphate; calcium and phosphorus balance; aminoaciduria; and calcemic response to exogenous parathyroid hormone.

INTRODUCTION

Osteomalacia that remits after resection of a coexisting mesenchymal tumor has been described in 13 patients (1–11). These patients with oncogenic osteomalacia presented with muscle weakness; bone roentgenograms showed changes of osteomalacia and/or rickets; and hypophosphatemia was present. Nine of these patients were adults and four, children, and the duration of symptoms ranged from 5 mo to 4 yr.

How tumors cause osteomalacia remains obscure. Neither ectopic secretion of a factor with calcitropic or phosphaturic effects, nor abnormalities in vitamin D action or metabolism have been demonstrated. The present investigation was designed to establish the diagnosis of oncogenic osteomalacia in a patient with giant cell tumor of bone and determine how the tumor caused this disorder. The data indicate that the osteomalacia was secondary to a deficiency of $1\alpha,25$-dihydroxycholecalciferol ($1\alpha,25$(OH)$_2$D$_3$) due to tumor-induced inhibition of vitamin D$_3$ metabolism.

Case description. A 42-yr-old woman presented with generalized bone pain. At age 34 she developed easy fatiguability, muscle weakness, and the sudden onset of back pain. She was a normal-appearing woman without physical evidence of bone disease. Serum calcium was 9.3 mg/100 ml (normal 8.5–10.5), serum phosphorus 1.3 mg/100 ml (normal 2.5–4.5), and serum alkaline phosphatase 135 U (normal 30–85). Bone roentgenograms showed decreased bone density, multiple cortical defects, and a lytic lesion ($2\times2$ cm) with sclerotic margins in the right iliac wing. Bone


Dr. Drezner is a recipient of a Research and Education Award from the Veterans Administration.

Received for publication 6 April 1977 and in revised form 14 July 1977.
biopsy from the left anterior iliac crest revealed osteomalacia and that from the lytic lesion, in the right iliac crest, showed fibroblastic proliferation and multinucleated giant cells consistent with an osteoclastoma. Family history was negative for bone disease, and serum calcium and phosphorus were normal in both parents, all siblings, and children. Chemical studies in the patient revealed normal urinary acidification, a decreased tubular maximum for the reabsorption of phosphate (TmP/GFR = 1.41 mg/100 ml [normal 2.5-4.55]), increased glycinuria, and normal fecal fat excretion. The diagnosis of acquired hypophosphatemic rickets with secondary hyperparathyroidism was made and therapy instituted (see below).

Over the next 7 yr bone pain became progressively worse, involving the back, pelvis, and long bones, and physical activity was markedly limited. Bone roentgenograms showed the development of nontraumatic pathologic fractures of the pelvis and expansion of the lytic lesion in the right iliac crest. During this period the patient received ergocalciferol (50,000-200,000 U/day), calcium (1-2 g/day), and phosphorus (2-4 g/day), alone and in combination. In spite of therapy, the serum concentration of calcium and phosphorus remained unchanged. Lack of therapeutic success prompted reevaluation in 1975 and repeat biopsy of the expanding lytic lesion showed a neoplasm containing many giant cells with 10-15 nuclei/cell, consistent with giant cell tumor of bone. The coexistence of giant cell tumor of bone and osteomalacia suggested the diagnosis of oncogenic osteomalacia and the patient was referred for evaluation. In preparation for study all medicines were discontinued for 10 mo.

Physical examination revealed a normal-appearing woman. There was pain on percussion over the lumbar sacral spine and pain on internal and external rotation or flexion of the right hip. Muscular strength appeared intact but was difficult to assess in the right leg secondary to pain on movement. Chvostek and Trousseau signs were absent.

METHODS

The patient was hospitalized in the Duke University Medical Center Clinical Research Unit and informed consent obtained for all studies. Dietary phosphorus was maintained at 1,200 mg/day and dietary calcium at 800 mg/day.

Bovine parathyroid extract for parenteral use of proved activity was obtained from Eli Lilly and Company (Indianapolis, Ind.). \( \text{Ia}_{25} \text{OH}_2 \text{D}_3 \) for oral administration was supplied by the Chemical Research Department, Hoffmann-La Roche, Inc. (Nutley, N. J.).

Biochemical studies. Serum calcium (normal 8.5-10.5 mg/100 ml), creatinine (normal 0.7-1.2 mg/100 ml), and alkaline phosphatase (normal 30-100 U) were measured on the multichannel Technicon Autoanalyser (Technicon Instruments Corp., Tarrytown, N. Y.). Serum phosphorus (normal 2.5-4.5 mg/100 ml) was determined by the colorimetric method of Dryer et al. (12). Urine specimens were stored at -20°C before analysis of calcium (by atomic absorption spectrophotometry), phosphorus (13), creatinine (14), and amino acids (15). Fecal fat excretion was measured by the method of Van de Kamer et al. (16) on 72-h fecal collections marked by carmine red dye and collected during ingestion of 70 g fat/day. Urinary D-xylose was measured (17) in 5-h urine specimens after the ingestion of 25 g of D-xylose.

Balance studies and assessment of renal phosphate handling. Calcium and phosphorus balance were determined by measuring dietary phosphorus and calcium in weighed duplicate portions of the ingested diet and subtracting urinary and fecal calcium or phosphorus excretion over 5-day periods. Studies were performed after at least 2 wk of equilibration on diet alone or diet and medication. Fecal collections were marked by carmine red dye. Aliquots of homogenized diet and feces were ashed at 700°C for 2-3 h, and the samples were solubilized in 6 N hydrochloric acid. Calcium was measured in these specimens by atomic absorption spectrophotometry. Phosphorus concentration was determined by a modification of the method of Dryer et al. (12), wherein samples and standards were in 0.6 M hydrochloric acid.

The tubular maximum for the reabsorption of phosphate normalized to glomerular filtration rate (TmP/GFR) was calculated by the method of Bijvoet (18). Estimation of the normalized tubular maximum of phosphate is possible from the published nomogram (18) and unpublished observations in our laboratory have confirmed that the estimated value does, in fact, accurately approximate the value of TmP/GFR determined during phosphate infusion. For these studies serial 1-h urine collections on selected mornings were preceded by a water load of 20 ml/kg body wt. The urine phosphate (13) and creatinine (14) were determined in each specimen, serum determinations of phosphorus (12) and creatinine obtained at the midpoint of each collection, and the TmP/GFR estimated by appropriate calculations and use of the nomogram. The values reported are the mean±SEM of 20 determinations.

Radioimmunoassays and competitive binding protein assays. Serum parathyroid hormone was measured by three separate radioimmunoassays. A carboxy-terminal-specific assay (normal <40 µl eq/ml) employing GP,M antibody was purchased from the Mayo Medical Laboratory Rochester, Minn.) (19). An amino-terminal-specific assay (normal <0.125 ng/ml) employing a guinea pig antibody raised against the synthetic (1-34) amino-terminal peptide of human parathyroid hormone was performed by Dr. Samuel Wells, Duke University Medical Center, according to the methods of Fischer et al. (20). Dr. Joel Habener (Massachusetts General Hospital, Boston, Mass.) measured parathyroid hormone (normal <10 µl eq/ml) by a primarily carboxy-terminal immunoassay employing the GP1 antibody (21).

Plasma 25-hydroxycholecalciferol (25[OH]D3) and 1a,25-(OH)2D3 concentrations were measured by Dr. Mark Huasler, University of Arizona Health Sciences Center, Tucson, according to previously published methods (22, 23). The results are presented as the mean±SEM of triplicate determinations.

Bone studies. Bone biopsies were obtained from the left anterior iliac crest under local anesthesia and the specimens preserved in 70% alcohol. Bone morphology was assayed and quantitative analysis performed by Dr. Jennifer Jowsey, Mayo Clinic, Rochester, Minn., employing previously described techniques (24, 25).

1a,25(OH)2D3 Deficiency in Oncogenic Osteomalacia 1047
RESULTS

Metabolic cause of the osteomalacia. A carefully documented dietary and medication history excluded fluoride as a cause of the osteomalacia. A negative family history of bone disease, normal serum alkaline phosphatase activity (95±6 U), and the absence of detectable phosphoethanolamine in the urine eliminated adult-onset hypophosphatasia. Fecal fat excretion of 2.5 g/day (normal <5 g/day) and urinary D-xylose excretion of 4.5 g/5 h (normal >2.5 g/5 h) precluded impaired vitamin D absorption, secondary to steatorrhea. A serum pH of 7.42 and generation of a urine pH of 3.50 (normal <4.5) in response to an ammonium chloride infusion excluded systemic acidosis and renal tubular acidosis.

A history of normal dietary intake, normal liver and renal function tests (creatinine clearance 99.5 ml/min), and lack of drug exposure (e.g., phenobarbital and dilantin) indicated no obvious cause for vitamin D₃ deficiency or altered vitamin D₃ metabolism. Nevertheless, we measured the vitamin D₃ metabolites. The serum 25(OH)D₃ concentration was 27±1 ng/ml (normal 15–40), confirming the impression of normal vitamin D₃ stores and normal cholecalciferol 25-hydroxylase activity. In contrast, the serum 1α,25-(OH)₂D₃ concentration was 1.6±0.1 ng/100 ml (normal 2.1–4.5), an abnormally low value, indicating that a deficiency of this active vitamin D₃ metabolite might be related to the pathogenesis of the osteomalacia.

Role of 1α,25(OH)₂D₃ in the pathogenesis of oncogenic osteomalacia. Tests designed to measure calcium and phosphorus homeostasis and parathyroid function were performed in the base-line state. After completion of these measurements, 1α,25(OH)₂D₃ was administered orally in an initial dose of 0.5 μg/day, gradually increased to a maintenance dose of 3.0 μg/day (0.06 μg/kg per day). After 2 wk of maintenance therapy, the biochemical studies were repeated. Subsequently, after cessation of therapy and upon return of the biochemical abnormalities to values comparable to the base line (serum calcium 8.9 mg/100 ml; serum phosphorus 1.6 mg/100 ml; and TmP/GFR 0.62 mg/100 ml [see below for comparison]), the tumor was resected. After surgery the patient received no medication, and after several weeks the biochemical studies were repeated.

The mean base-line serum calcium concentration

\[
\begin{array}{c|c|c}
\text{BASE LINE} & \text{1α,25(OH)₂D₃ TREATMENT} & \text{AFTER TUMOR RESECTION} \\
\hline
\text{CALCIUM AND PHOSPHORUS BALANCE STUDIES} & & \\
\text{SERUM CALCIUM (mg/dl)} & 10.0 & \\
\text{SERUM PHOSPHORUS (mg/dl)} & 9.0 & \\
\text{CALCIUM BALANCE (mg/day)} & 500 & 1000 \\
\text{PHOSPHORUS BALANCE (mg/day)} & 500 & 1000 \\
\hline
\end{array}
\]

\text{FIGURE 1} Calcium and phosphorus balance studies in the base-line state, during treatment with 1α,25(OH)₂D₃ (3 μg/day), and after tumor resection, shown according to the methods of Reifenstein et al. (26). The dietary calcium and phosphorus are plotted below the 0 line. Fecal excretion is represented by the hatched areas and urinary excretion by the open areas. Extension of the columns above 0 indicate negative balance and termination of the columns below 0 indicate positive balance.
was 8.92±0.11 mg/100 ml (range 8.6–9.4), a value within normal limits. In contrast, the base-line serum phosphorus concentration was below normal, mean 1.48±0.07 mg/100 ml (range 1.2–1.8). In response to both 1α,25(OH)2D3 therapy and tumor resection, the serum calcium remained normal (9.50±0.07 and 8.81±0.21 mg/100 ml, respectively), while the serum phosphorus concentration increased to values within the normal range (3.19±0.03 and 3.22±0.03 mg/100 ml).

TmP/GFR was quantitated in the three study periods. In the base-line state the TmP/GFR was 0.82±0.03 mg/100 ml, a value below normal (2.5–4.55), indicating that a renal phosphate leak was present. After treatment with 1α,25(OH)2D3 or tumor resection, however, the TmP/GFR rose to 2.95±0.01 and 2.55±0.07 mg/100 ml, respectively.

The calcium and phosphorus balances in the three study periods are shown in Fig. 1. In the base-line period the calcium balance averaged –95 mg/day while the phosphorus balance averaged –210 mg/day. The negative calcium balance was secondary to gastrointestinal malabsorption (110 mg/day absorbed; normal 325±25 [27]), while the negative phosphorus balance resulted from both gastrointestinal malabsorption (525 mg/day absorbed; normal 771 [28]) and renal phosphate loss (TmP/GFR, 0.82 mg/100 ml). Treatment with 1α,25(OH)2D3 or tumor resection resulted in a positive calcium balance (162 and 155 mg/day, respectively) and a positive phosphorus balance (205; 150 mg/day).

We also measured the calcemic response to exogenously administered parathyroid extract. Parathyroid extract (200 U) was administered intramuscularly every 6 h for 48 h or until a rise in the serum calcium to elevated values occurred. While in normal controls the serum calcium increased more than 1.0 mg/100 ml during this treatment (29–32), in our patient there was a subnormal increase in calcium in the base-line state (0.9 mg/100 ml at 50 h). In response to therapy with 1α,25(OH)2D3 and after tumor resection, the calcemic response returned to normal, with an increase of 2.5 and 2.4 mg/100 ml, respectively, at 14 h.

Increased urinary excretion of one or more amino acids has previously been reported in patients with oncogenic osteomalacia (2, 4, 6, 10). In the base-line state, our patient excreted markedly elevated quantities of glycine, leucine, serine and arginine, as well as increased amounts of several additional amino acids (Table I). 1α,25(OH)2D3 therapy and tumor resection reduced the urinary amino acid excretion to normal levels.

Many of the abnormalities noted might have been due to elevated levels of parathyroid hormone, and the response to 1α,25(OH)2D3 therapy or tumor resection due to alterations in parathyroid hormone concentration. However, at presentation the serum parathyroid hormone concentration was normal, as measured by three methods: a carboxy-terminal assay from the Mayo Medical Laboratory (25 μl eq/ml); an aminoterminal assay with antibody directed against the 1–34 amino acid fragment (0.016 ng/ml); and a primarily carboxy-terminal assay developed against the intact molecule (4 μl eq/ml). Furthermore, no significant change in the parathyroid hormone concentration as determined by the first two methods occurred upon treatment with 1α,25(OH)2D3 (22 μl eq/ml and 0.018 ng/ml, respectively) or resection of the tumor (27 μl eq/ml and 0.025 ng/ml, respectively).

Finally, the effects of 1α,25(OH)2D3 therapy on bone morphology are shown in Fig. 2. The bone biopsy obtained at presentation had large areas of unmineralized osteoid and widened osteoid seams. In contrast, the bone biopsy after treatment with 1α,25(OH)2D3 had considerably less unmineralized osteoid. These observations were confirmed by quantitative microradiography (Table II). A decrease in unmineralized osteoid, an increase in the mineralization-

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>Base line</th>
<th>1α,25(OH)2D3 (3 μg/day)</th>
<th>After tumor resection</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>μmol/g creatinine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine</td>
<td>528</td>
<td>173</td>
<td>86</td>
<td>36–394</td>
</tr>
<tr>
<td>Valine</td>
<td>83</td>
<td>45</td>
<td>33</td>
<td>3–39</td>
</tr>
<tr>
<td>Glycine</td>
<td>3,798</td>
<td>1,890</td>
<td>1,829</td>
<td>419–2,285</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>38</td>
<td>20</td>
<td>7</td>
<td>1–98</td>
</tr>
<tr>
<td>Leucine</td>
<td>85</td>
<td>21</td>
<td>10</td>
<td>10–28</td>
</tr>
<tr>
<td>Proline</td>
<td>277</td>
<td>57</td>
<td>36</td>
<td>33–216</td>
</tr>
<tr>
<td>Threonine</td>
<td>272</td>
<td>167</td>
<td>45</td>
<td>50–226</td>
</tr>
<tr>
<td>Serine</td>
<td>735</td>
<td>308</td>
<td>198</td>
<td>94–538</td>
</tr>
<tr>
<td>Cysteine</td>
<td>18</td>
<td>15</td>
<td>7</td>
<td>4–26</td>
</tr>
<tr>
<td>Methionine</td>
<td>27</td>
<td>14</td>
<td>9</td>
<td>4–22</td>
</tr>
<tr>
<td>Hydroxyproline</td>
<td>111</td>
<td>47</td>
<td>49</td>
<td>39–267</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>73</td>
<td>43</td>
<td>29</td>
<td>8–128</td>
</tr>
<tr>
<td>Aspartic acid*</td>
<td>350</td>
<td>170</td>
<td>139</td>
<td>39–193</td>
</tr>
<tr>
<td>Glutamic acid†</td>
<td>625</td>
<td>300</td>
<td>106</td>
<td>100–492</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>115</td>
<td>47</td>
<td>32</td>
<td>4–166</td>
</tr>
<tr>
<td>Ornithine</td>
<td>290</td>
<td>103</td>
<td>148</td>
<td>76–212</td>
</tr>
<tr>
<td>Tryptophan</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>1–48</td>
</tr>
<tr>
<td>Arginine</td>
<td>906</td>
<td>185</td>
<td>200</td>
<td>43–223</td>
</tr>
<tr>
<td>Kynurenine</td>
<td>2</td>
<td>5</td>
<td>4</td>
<td>1–10</td>
</tr>
<tr>
<td>Cystathione</td>
<td>9</td>
<td>7</td>
<td>5</td>
<td>2–10</td>
</tr>
<tr>
<td>Cystine</td>
<td>118</td>
<td>52</td>
<td>60</td>
<td>16–66</td>
</tr>
<tr>
<td>Homocystine</td>
<td>7</td>
<td>4</td>
<td>1</td>
<td>1–10</td>
</tr>
</tbody>
</table>

* Includes asparagine.
† Includes glutamine.
Bone biopsies from the left iliac crest. The unstained, calcified section shows large areas of unmineralized osteoid, denoted by the arrows. At the conclusion of therapy with 1α,25-(OH)₂D₃ (3 μg/day), a decrease in the amount of unmineralized osteoid is evident.

DISCUSSION

Impaired conversion of vitamin D₃ to 1α,25(OH)₂D₃ is responsible for several vitamin D-refractory osteomalacia syndromes (chronic renal insufficiency [33, 34], anticonvulsant-induced osteomalacia [35, 36], and hereditary vitamin D-dependent rickets [37]). The present study indicates that oncogenic osteomalacia is another vitamin D-refractory syndrome, caused by faulty conversion of vitamin D₃ to its active metabolite, 1α,25(OH)₂D₃.

Our patient presented with a giant cell tumor of bone and osteomalacia, suggesting the diagnosis of oncogenic osteomalacia. Resolution of the biochemical abnormalities of the syndrome after tumor resection, and roentgenographic evidence of bone healing (data not shown), established this diagnosis.

A deficiency of 1α,25(OH)₂D₃ was suggested by measurements of the serum concentration of 25(OH)D₃ and 1α,25(OH)₂D₃. Upon administration of 1α,25(OH)₂D₃, the biopsy showed healing of the bone pathology (Fig. 2) and the biochemical abnormalities of the syndrome were corrected.

Two theories could explain the deficiency of 1α,25(OH)₂D₃ in our patient: defective conversion from 25(OH)D₃, or increased degradation of 1α,25(OH)₂D₃. Although the physiological requirement for 1α,25(OH)₂D₃ in the human has been estimated at 0.57 μg/day (38), the oral requirement for this compound in
a variety of disease states due to vitamin D3 deficiency is 0.04–0.08 μg/kg per day (38–41). In view of this information, the dose of 1α,25(OH)2D3 administered to our patient was probably in the physiological range. Resolution of the syndrome in response to this dose precludes increased degradation of this active vitamin D3 metabolite as the cause of 1α,25(OH)2D3 deficiency. Moreover, the inability to cure the osteomalacia with a dose of 200,000 U of ergocalciferol, 1,700 times the effective dose of 1α,25(OH)2D3, establishes that defective conversion of vitamin D3 to its active metabolite underlies this disorder. Since the normal 25(OH)D3 concentration indicates adequate cholecalciferol-25-hydroxylase activity, a reasonable interpretation of these findings is that a block exists in the metabolism of 25(OH)D3 to 1α,25(OH)2D3.

It seems clear that the decreased production of 1α,25(OH)2D3 was due to elaboration by the tumor of a factor that inhibited its synthesis. Although the precise control mechanisms operative in the kidney for the enzymatic hydroxylation of precursor vitamin D (25(OH)D3) to the active product are unknown, the interaction of parathyroid hormone, renal tubule cell cyclic AMP, and renal cell phosphate concentration has been determined (42). Our patient, however, had none of the abnormalities reported that impair vitamin D activation. Rather, sporadic onset of osteomalacia and 1α,25(OH)2D3 deficiency occurred concurrently with the mesenchymal tumor, and the osteomalacia was cured after tumor resection. Thus, a role for the tumor in generating the 1α,25(OH)2D3 deficiency is evident.

Although the biochemical features of this syndrome were for the most part characteristic of vitamin D deficiency (43), several measurements were at variance. First, there was a normal serum calcium concentration in our patient and in other patients with oncogenic osteomalacia. The serum calcium concentration in simple vitamin D deficiency is characteristically low (43, 44). However, the available data in several studies (45–48) show numerous examples of normal serum calcium in subjects with vitamin D-deficiency osteomalacia. In the subject of this study, the ability to maintain normocalcemia appears to be multi-factorial: (a) there was negligible urinary calcium excretion; (b) active bone mineralization was scant (Table II); (c) severe phosphate depletion probably increased mobilization of calcium from bone (49). Secondly, the presence of severe renal phosphate wasting without a measurable increase in parathyroid hormone was paradoxical. Although the radioimmunoassays employed may not reflect total circulating levels of active parathyroid hormone, the use of three separate assays with different antigenic specificities makes this unlikely. However, confirmation of normal parathyroid hormone activity by measurement of urinary cyclic AMP excretion was precluded since tumor-secreted product(s) may independently alter urinary cyclic AMP. Nevertheless, phosphaturia may be a direct effect of 1α,25(OH)2D3 deficiency. Recent studies support this possibility. De Luca and associates (50, 51) have shown that 1α,25(OH)2D3 increases renal phosphate reabsorption in thyroparathyroidectomized dogs. Further, Brautbar et al. (52) reported that 1α,25(OH)2D3 likewise increased renal phosphate reabsorption in thyroparathyroidectomized animals supplemented with a constant infusion of small amounts of parathyroid hormone. Thus renal phosphate wasting is consistent with the effects of 1α,25(OH)2D3 deficiency and normal parathyroid function. Although these observations provide an adequate explanation for the contrasting abnormalities of the oncogenic osteomalacia syndrome, we cannot exclude the possibility that a direct effect of other tumor-secreted product(s) contributes to the normocalcemia and renal phosphate wasting.

Thus oncogenic osteomalacia can be a form of vitamin-D-refractory osteomalacia due to altered vitamin D3 metabolism. On the basis of our data we propose that the sequence of metabolic events underlying this disorder is: (a) a factor is synthesized and secreted by the tumor; (b) the factor decreases the synthesis of 1α,25(OH)2D3 by inhibiting 25-hydroxycholecalciferol-1-hydroxylase activity; and (c) the resultant 1α,25(OH)2D3 deficiency causes the osteomalacia and the attendant biochemical abnormalities. The role of a tumor in inducing the deficiency of 1α,25(OH)2D3 not only has theoretical significance for tumor biology but in addition has potential practical importance in guiding therapy of surgically unmanageable cases.

ACKNOWLEDGMENTS

We are indebted to Dr. Jenifer Jowsey for performing the analyses of the bone biopsies; to Dr. Mark Haussler for measurement of 1α,25(OH)2D3; to Drs. Samuel Wells and Joel Habener for measurement of parathyroid hormone; to Drs. George J. Ellis III, Francis A. Neelon, and Kenneth A. McCarty, Jr., for referral of the patient and helpful discussions; to Dr. John Harrelson for surgical care of the patient; to Dr. Harold E. Lebovitz for generous support; and to Ms. Lu Ann Wingate and Ms. Holly B. Curtis for excellent technical assistance.

This study was supported by grants from the National Institute of Arthritis, Metabolic and Digestive Diseases of the National Institutes of Health (AM 01324, AM 07012), and by grant MO 1 FR 30 from the Clinical Research Center Branch Division of Research Facilities and Resources, U. S. Public Health Service.

REFERENCES


1α,25(OH)2D3 Deficiency in Oncogenic Osteomalacia 1051


38. Norman, A. W., and H. Henry. 1974. The role of the


1α,25(OH)2D3 Deficiency in Oncogenic Osteomalacia 1053